Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
APLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.70 - $58.12
Previous CloseN/A
Volume215.04K
Average Volume (3M)1.82M
Market Cap
$2.75B
Enterprise Value$4.03B
Total Cash (Recent Filing)-$4.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.88
Next Earnings
May 01, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.60
Shares Outstanding125,515,816
10 Day Avg. Volume2,304,048
30 Day Avg. Volume1,824,311
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.88
Price to Cash Flow (P/CF)39.10
P/FCF Ratio39.20
Enterprise Value/Market Cap1.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.81
Enterprise Value/Ebitda-26.09
Forecast
1Y Price Target
$42.33Price Target Upside86.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Drug ApprovalThe FDA has granted priority review for Empaveli, indicating confidence in its potential impact for patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.
Market PotentialThere is a significant opportunity for Empaveli due to the unmet need and impressive efficacy observed in the VALIANT study, suggesting a strong market potential.
Bears Say
Funding ConcernsAPLS sentiment has been very tough recently with concerns about funding issues with third-party charitable organizations.
Investor SentimentNear-term Syfovre growth issues persist, which won't help investor sentiment on the name.
---
Ownership Overview
3.43% Insiders
22.95% Mutual Funds
39.76% Other Institutional Investors
19.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $21.70 and its highest was $58.12 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Apellis Pharmaceuticals Inc’s market cap is $2.75B.
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is May 01, 2025 which is in 28 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Feb 28, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.369 by $0.079.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -0.34.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 125,515,816 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.369. Following the earnings report the stock price went down -3.269%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in APLS
---
Apellis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.33 (86.64% Upside)
$42.33 (86.64% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 8.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.01%
12-Months-Change
Fundamentals
Return on Equity
-93.55%
Trailing 12-Months
Asset Growth
12.21%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
---
APLS Company Deck
---
APLS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant achievements in revenue growth, successful product launches, and pipeline advancements. However, there are challenges with temporary revenue impacts due to external factors and competitive pressures. Despite a net loss reported for the quarter, the company's strong financial position and strategic initiatives provide a positive outlook.Read More>---
APLS Stock 12 Month Forecast
Average Price Target
$42.33
▲(86.64% Upside)
Technical Analysis
Alnylam Pharma
―
Neurocrine
―
Regeneron
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering APLS
1 Year
1 Year Success Rate
13/29 ratings generated profit
1 Year Average Return
+3.98%
assigned a buy rating 5 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 44.83% of your transactions generating a profit, with an average return of +3.98% per trade.
---